Empagliflozin for mild-to-moderate ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This early trial studies whether empagliflozin can improve ulcerative colitis symptoms and is safe for people with mild to moderate disease. If it works, it may reduce ongoing colon inflammation and help people feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with mild-to-moderate ulcerative colitis.
- Your diagnosis was confirmed with symptoms plus colon scope (endoscopy) and biopsy, to show long-lasting inflammation and rule out other causes.
- You do not have Crohn’s disease or another type of inflammatory bowel disease.
- You have never had a serious allergic reaction to empagliflozin (or its ingredients).
- You are not on dialysis and your kidney function is not severely reduced (eGFR is 20 or higher).
- You do not have long-term bladder/urinary infections or long-term genital infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether dapagliflozin (a medicine often used for diabetes) can help calm inflammation in people with mild to moderate ulcerative colitis. It's a new way of treating UC by working with the body's natural cleanup process.
This trial tests if empagliflozin, a medicine used for diabetes, can help protect kidney function in people with active lupus nephritis. You may be eligible if you have a lupus kidney flare with significant protein in your urine.
This trial tests if empagliflozin, a medicine that helps control blood sugar and protect the kidneys, is safe and effective for people with type 2 diabetes who have very low kidney function (eGFR between 10 and 20). It aims to see if the drug can still benefit the heart and kidneys at this stage.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This study tests a pill called empagliflozin (commonly used for diabetes) to see if it can help people with chronic kidney disease who do not have diabetes. It looks at whether the drug can protect your blood vessels and slow down how quickly your kidneys get worse.
This trial tests if the diabetes drug empagliflozin can help reduce inflammation in people with stable coronary artery disease who are planning to have a stent placed. It may offer a new way to protect heart health.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.